The future of cytopathology in Europe. Will the wider use of HPV testing have an impact on the provision of cervical screening?

Cytopathology

Volumn 18, Issue 5, 2007, Pages 278-282

  Gray, W ^a   Bayer Pietsch, E ^b   Chieco, P ^c   Cochand Priollet, B ^d   Desai, M ^e   Drijkoningen, M ^f   Griffin, M ^g   Hagmar, B ^h   Kapila, K ⁱ   Kloboves Prevodnik, V ^j   Kobayashi, T ^k   Krogerus, L ^l   Majak, B ^h   Mihailovici, M ^m   Olszewski, W ⁿ   Schenck, U ^b   Schmitt, F ^o   Shabalova, I ^p   Shapiro, N ^p   Smith, J ^e   Tani, E ^q   Totsch, M ^b   Vass, L ^r   Wiener, H ^s   Herbert, A ^e   more..

^a Editorial Advisor Cytopathology ^*

^b German Cytology Society   (Germany)

^c Italian Society of Pathological Anatomy and Diagnostic Cytology

^d French Society of Clinical Cytology

^e British Society of Clinical Cytology   (United Kingdom)

^f Belgian Society for Clinical Cytology

^g ST JAMES S HOSPITAL   (Ireland)

^h Norwegian Society of Clinical Cytology   (Norway)

ⁱ KUWAIT UNIVERSITY   (Kuwait)

^j Slovenian Society of Clinical Cytology

^k Medical Care Center   (Japan)

^l Finnish Cytology Society

^m Romanian Cytology Society

ⁿ Polish Society of Pathology

^o Portuguese Cytology Society

^p All Russian Scientific Society of Clinical Laboratory Diagnostics

^q Swedish Society of Clinical Cytology   (Sweden)

^r Hungarian Society for Clinical Cytology

^s Austrian Society for Clinical Cytology

more..

Author keywords

Cervical screening; Cytology; European experience; HPV testing; Quality control; Training; Triage

Indexed keywords

CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; CYTOPATHOLOGY; EUROPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; INFECTION RISK; MASS SCREENING; MEDICAL EDUCATION; MEDICAL PERSONNEL; OPPORTUNISTIC INFECTION; PAPANICOLAOU TEST; PRIORITY JOURNAL; REVIEW; SCREENING TEST; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS DETECTION; WART VIRUS;

CYTOLOGICAL TECHNIQUES; EUROPE; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY, CLINICAL; UTERINE CERVICAL NEOPLASMS;

EID: 34748863634     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2007.00487.x     Document Type: Review

References (6)

1. Bulkmans NWJ, Rozendaal L, Snijders PJF et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2003 110 : 94 101.
2. Cuzick J, Szarewski A, Cubie H et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003 362 : 1871 6.
3. Desai M, Cubie H. The HPV test in cervical screening: a brave new world? Cytopathology 2005 16 : 3 6.
4. Kitchener HK, Almonte M, Wheeler P et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006 95 : 56 61.
5. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virological versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004 96 : 280 93.
6. Zielinski GD, Bais AG, Helmerhorst ThJ et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004 59 : 543 53.